On this page
Cardiogen Quick Reference (20 mg Vial)
- Vial contents
- 20 mg Cardiogen
- Final volume
- 3 mL
- Concentration
- 6.67 mg/mL
- One U-100 unit
- 66.67 mcg in 0.01 mL
Research context: Read the published Cardiogen research overview for broader identity, mechanism, safety, and evidence context.
Cardiogen Dosage Chart
Dosing & Reconstitution Guide
Community-Reported Use Calculations (3.0 mL = 6.667 mg/mL)
Community-Reported Use Calculations (3.0 mL = 6.667 mg/mL)
| Research Period | Amount per Administration | U-100 Units (mL) |
|---|---|---|
| 10 days | 1 mg | 15 units (0.15 mL) |
| 20 days | 1 mg | 15 units (0.15 mL) |
| 10 days | 2 mg | 30 units (0.30 mL) |
| 20 days | 2 mg | 30 units (0.30 mL) |
Frequency: Once daily in the reviewed community descriptions. Each row is an independent calculation, not a titration schedule.
Research reference only: The 1 to 2 mg once-daily, 10 to 20 day patterns are nonclinical community descriptions. No human Cardiogen trial establishes dose, route, safety, efficacy, or an approved regimen. Academic references support identity, mechanisms, and evidence limits, not these schedule numbers.
Reconstitution Steps
- Clean the vial stopper and diluent stopper with alcohol; allow both to dry.
- Draw exactly 3.0 mL of bacteriostatic water with a new sterile syringe, then inject it slowly down the inside wall of the vial.
- Gently swirl or roll until dissolved. Do not shake.
- Label the vial with compound, concentration, and reconstitution date. Refrigerate at 2–8 °C (36–46 °F) and protect from light.
Storage note: Avoid repeated freeze-thaw cycles. No Cardiogen-specific post-reconstitution stability or discard period has been established; follow the lot-specific supplier documentation for any discard date.
Supplies Needed
Choose the supply row that matches the single calculation period being reviewed. Do not add the rows together.
- Peptide Vials (Cardiogen, 20 mg each):
- 10 days at 1 mg/day: 1 vial
- 20 days at 1 mg/day: 1 vial
- 10 days at 2 mg/day: 1 vial
- 20 days at 2 mg/day: 2 vials
- Insulin Syringes (U-100):
- 10-day calculations: 10 syringes
- 20-day calculations: 20 syringes
- Bacteriostatic Water (10 mL bottle):
- One-vial calculations: 3.0 mL
- Two-vial calculation: 6.0 mL
- Alcohol Swabs:
- 10-day calculations: 20 swabs
- 20-day calculations: 40 swabs
Sharps safety: Place used needles and syringes immediately in an approved sharps container.
Peptide Reconstitution Simulator
Practice preparing this vial with the verified strength and final volume from this protocol.
Cardiogen Vial and Research Context
- Reconstitute: Add 3.0 mL bacteriostatic water for a calculated concentration of 6.667 mg/mL.
- Vial contents: 20 mg Cardiogen.
- U-100 conversion: At 6.667 mg/mL, 1 unit = 0.01 mL = 66.667 mcg.
- Storage: Refrigerate at 2–8 °C (36–46 °F) and protect from light.
Cardiogen (AEDR) is a short peptide studied mainly in rat tissue, animal, cell, and biochemical models.[1][2][3][4] These findings do not establish a human cardiovascular treatment protocol.
What the Cardiogen Research Does and Does Not Establish
Cardiogen is identified in biochemical literature as the tetrapeptide Ala-Glu-Asp-Arg (AEDR).[4] Direct studies involve rat heart explants, other cell systems, or animal models, not a controlled human dosing trial.[1][2][3][5]
No published human dosing trial establishes a validated Cardiogen amount, route, frequency, duration, safety profile, or treatment effect. The dosage chart is therefore labeled as community-reported use, and the academic references support only identity, mechanisms, model findings, and evidence limits.
Mechanistic papers and reviews discuss DNA, histone, cytoskeletal, transport, and gene-expression hypotheses.[4][5][6][15][16][9] Cardiovascular context papers address fibrosis and p53 biology but do not validate Cardiogen as a clinical therapy.[10][11][12][13] The current heart-failure guideline does not establish Cardiogen treatment.[14]
20 mg Vial Calculation Notes
- 20 mg divided by 3.0 mL equals 6.667 mg/mL.
- One U-100 unit equals 0.01 mL or 66.667 mcg.
- 1 mg equals 15 units (0.15 mL).
- 2 mg equals 30 units (0.30 mL).
Evidence Limits and Safety
References
- 1Zakutskii et al., 2006, PMID 17152728 – Rat organotypic heart-tissue study reporting Cardiogen at 0.05 ng/mL.
- 2Chalisova et al., 2009, PMID 20210190 – Rat myocardial-explant study reporting Cardiogen at 10^-12 M and measuring proliferation and p53 expression.
- 3Levdik and Knyazkin, 2010, PMID 20396706 – Rat M-1 sarcoma study reporting Cardiogen injections; the abstract does not provide the numeric dose or schedule.
- 4Fedoreyeva et al., 2013, PMID 23581987 – Biochemical study identifying Cardiogen as Ala-Glu-Asp-Arg and examining histone and oligonucleotide interactions.
- 5Keavinson et al., 2012, PMID 22977870 – Cell-model study of AEDR and expression of cytoskeletal and nuclear-matrix proteins.
- 6Keavinson et al., 2011, PMID 22442805 – Laboratory study of short-peptide binding with DNA and endonuclease activity.
- 7Khavinson et al., 2022, PMID 35887081 – Review of proposed transport mechanisms for biologically active ultrashort peptides.
- 8Kheifets et al., 2010, PMID 20586252 – Human-derived fibroblast cell-aging model involving short peptide bioregulators; this is not a human trial.
- 9Keavinson et al., 2021, PMID 34834147 – Systematic review of short-peptide regulation of gene expression.
- 10Talman and Ruskoaho, 2016, PMCID PMC5010608 – Review of cardiac fibrosis, repair, remodeling, and regeneration after myocardial infarction.
- 11Men et al., 2020, PMCID PMC11073000 – Review of context-dependent roles of p53 in cardiovascular health and disease.
- 12Long et al., 1997, PMID 9169493 – Laboratory study of p53 and hypoxia-induced apoptosis in cultured neonatal rat cardiac myocytes.
- 13Webster et al., 1999, PMID 10430605 – Laboratory study showing cardiac-myocyte apoptosis can occur independently of p53 under specified conditions.
- 14Heidenreich et al., 2022, AHA/ACC/HFSA guideline – Clinical guideline for evidence-based heart-failure management. Cardiogen is not an established therapy in this guideline.
- 15U.S. FDA, Clinical Pharmacology Considerations for Peptide Drug Products – Regulatory guidance on clinical pharmacology evidence expected in peptide drug development.
- 16European Medicines Agency, Development and Manufacture of Synthetic Peptides – Scientific guideline addressing identity, quality, and impurity control for synthetic peptides.